Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) - Total Liabilities
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has total liabilities worth $5.43 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore EPRX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Eupraxia Pharmaceuticals Inc. Common Stock - Total Liabilities Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Eupraxia Pharmaceuticals Inc. Common Sto (EPRX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Eupraxia Pharmaceuticals Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Eupraxia Pharmaceuticals Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Diplomat Holdings Ltd
TA:DIPL
|
Israel | ILA1.12 Billion |
|
Chengdu Tianjian Technology Co Ltd
SHE:002977
|
China | CN¥91.33 Million |
|
Hanil Cement Co Ltd
KO:003300
|
Korea | ₩1.38 Trillion |
|
BHG Group AB (publ)
ST:BHG
|
Sweden | Skr4.57 Billion |
|
Shanghai Fudan Forward S&T Co Ltd
SHG:600624
|
China | CN¥828.67 Million |
|
ANGLO ASIAN MINING
F:A4A
|
Germany | €84.38 Million |
|
Shanghai Model Organisms Center Inc
SHG:688265
|
China | CN¥252.99 Million |
|
Precious Shipping Public Company Limited
BK:PSL
|
Thailand | ฿9.21 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Eupraxia Pharmaceuticals Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Eupraxia Pharmaceuticals Inc. Common Sto.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eupraxia Pharmaceuticals Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
The table below shows the annual total liabilities of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.10 Million | -83.98% |
| 2023-12-31 | $19.37 Million | +20.10% |
| 2022-12-31 | $16.13 Million | +33.27% |
| 2021-12-31 | $12.10 Million | -47.64% |
| 2020-12-31 | $23.12 Million | +7.94% |
| 2019-12-31 | $21.42 Million | +49.30% |
| 2018-12-31 | $14.34 Million | +1849.47% |
| 2017-12-31 | $735.82K | -- |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more